Free Trial

Cardinal Health (CAH) Stock Forecast & Price Target

Cardinal Health logo
$118.28 +1.28 (+1.09%)
(As of 12/20/2024 05:31 PM ET)

Cardinal Health - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
5
Buy
8

Based on 13 Wall Street analysts who have issued ratings for Cardinal Health in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 5 have given a hold rating, and 8 have given a buy rating for CAH.

Consensus Price Target

$127.50
7.80% Upside
According to the 13 analysts' twelve-month price targets for Cardinal Health, the average price target is $127.50. The highest price target for CAH is $139.00, while the lowest price target for CAH is $107.00. The average price target represents a forecasted upside of 7.80% from the current price of $118.28.
Get the Latest News and Ratings for CAH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Cardinal Health and its competitors.

Sign Up

CAH Analyst Ratings Over Time

TypeCurrent Forecast
12/22/23 to 12/21/24
1 Month Ago
11/22/23 to 11/21/24
3 Months Ago
9/23/23 to 9/22/24
1 Year Ago
12/22/22 to 12/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
3 Buy rating(s)
Hold
5 Hold rating(s)
5 Hold rating(s)
4 Hold rating(s)
6 Hold rating(s)
Sell
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$127.50$123.00$119.36$96.77
Forecasted Upside7.80% Upside-0.24% Downside6.73% Upside-4.50% Downside
Consensus Rating
Moderate Buy
Hold
Moderate Buy
Hold

CAH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CAH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Cardinal Health Stock vs. The Competition

TypeCardinal HealthMedical CompaniesS&P 500
Consensus Rating Score
2.62
2.81
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside7.80% Upside25,828.93% Upside14.52% Upside
News Sentiment Rating
Positive News

See Recent CAH News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/17/2024Morgan Stanley
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$127.00 ➝ $136.00+18.21%
12/13/2024Wells Fargo & Company
3 of 5 stars
S. Baxter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Equal Weight$101.00 ➝ $127.00+8.12%
12/4/2024Mizuho
2 of 5 stars
A. Hynes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold ➝ Outperform$139.00+12.79%
11/4/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$119.00 ➝ $124.00+9.48%
11/4/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$134.00 ➝ $139.00+21.30%
11/4/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$117.00 ➝ $133.00+14.53%
9/11/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$115.00 ➝ $125.00+10.34%
8/21/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$111.00 ➝ $123.00+12.23%
8/15/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$130.00 ➝ $137.00+28.81%
8/15/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetIn-Line ➝ In-Line$105.00 ➝ $115.00+8.12%
7/19/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$115.00 ➝ $107.00+11.98%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/26/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$125.00+15.64%
8/16/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform ➝ Market Perform$88.00 ➝ $90.00-0.56%
7/17/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$91.00 ➝ $99.00+6.29%
6/12/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$90.00 ➝ $100.00+15.82%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 09:30 AM ET.


Should I Buy Cardinal Health Stock? CAH Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, December 11, 2024. Please send any questions or comments about these Cardinal Health pros and cons to contact@marketbeat.com.

Cardinal Health
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Cardinal Health, Inc.:

  • Cardinal Health, Inc. has recently received positive upgrades from multiple analysts, with price targets raised significantly, indicating strong market confidence. For instance, Argus increased their target from $115.00 to $125.00, suggesting potential for price appreciation.
  • The current stock price is $117.16, which is below the average price target of $124.58, indicating that there may be room for growth in the stock value.
  • Despite a slight decline in quarterly revenue, the company reported earnings per share (EPS) of $1.88, surpassing analysts' expectations of $1.62, which reflects strong operational performance.
  • Cardinal Health, Inc. has a relatively low beta of 0.61, suggesting that the stock is less volatile compared to the market, which can be appealing for risk-averse investors.
  • The company has a consistent dividend payout, with a recent quarterly dividend of $0.5056 per share, translating to an annualized yield of approximately 1.73%, providing a steady income stream for investors.

Cardinal Health
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Cardinal Health, Inc. for these reasons:

  • Cardinal Health, Inc. experienced a year-over-year revenue decline of 4.3%, which may raise concerns about the company's growth prospects and market competitiveness.
  • The company has a negative return on equity of 56.56%, indicating that it is currently not generating profit from its equity investments, which could deter potential investors.
  • One analyst has rated the stock with a sell rating, which may signal caution among some investors regarding the stock's future performance.
  • The recent downgrade from StockNews.com from a "strong-buy" to a "buy" rating may indicate a shift in sentiment that could affect investor confidence.
  • With a market cap of $28.35 billion, Cardinal Health, Inc. may face challenges in scaling operations or competing with larger healthcare firms, which could limit growth opportunities.

CAH Forecast - Frequently Asked Questions

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Cardinal Health is $127.50, with a high forecast of $139.00 and a low forecast of $107.00.

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cardinal Health in the last year. There are currently 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CAH shares.

According to analysts, Cardinal Health's stock has a predicted upside of 7.80% based on their 12-month stock forecasts.

Over the previous 90 days, Cardinal Health's stock had 1 upgrade by analysts.

Cardinal Health has been rated by research analysts at Barclays, Deutsche Bank Aktiengesellschaft, Mizuho, Morgan Stanley, UBS Group, and Wells Fargo & Company in the past 90 days.

Analysts like Cardinal Health less than other "medical" companies. The consensus rating score for Cardinal Health is 2.62 while the average consensus rating score for "medical" companies is 2.81. Learn more on how CAH compares to other companies.


This page (NYSE:CAH) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners